A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer

BACKGROUND: Pancreatic cancer is the fourth most common cause of cancer related death in Western countries. Advantages in surgical techniques, radiation and chemotherapy had almost no impact on the long term survival of affected patients. Therefore, the need for better treatment strategies is urgent...

Descripción completa

Detalles Bibliográficos
Autores principales: Mihaljevic, Andre, Büchler, Peter, Harder, Jan, Hofheinz, Ralf, Gregor, Michael, Kanzler, Stephan, Schmiegel, Wolff, Heinemann, Volker, Endlicher, Esther, Klöppel, Günter, Seufferlein, Thomas, Geissler, Michael
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661037/
https://www.ncbi.nlm.nih.gov/pubmed/19133157
http://dx.doi.org/10.1186/1471-2482-9-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661037/
https://www.ncbi.nlm.nih.gov/pubmed/19133157
http://dx.doi.org/10.1186/1471-2482-9-1

Ejemplares similares